DK1848415T3 - Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose - Google Patents

Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose

Info

Publication number
DK1848415T3
DK1848415T3 DK06720863.7T DK06720863T DK1848415T3 DK 1848415 T3 DK1848415 T3 DK 1848415T3 DK 06720863 T DK06720863 T DK 06720863T DK 1848415 T3 DK1848415 T3 DK 1848415T3
Authority
DK
Denmark
Prior art keywords
rasagiline
treatment
multiple sclerosis
combination therapy
glatiramer acetate
Prior art date
Application number
DK06720863.7T
Other languages
English (en)
Inventor
Rivka Kreitman
Liat Hayardeny
Ruth Levy
Eran Blaugrund
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1848415T3 publication Critical patent/DK1848415T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DK06720863.7T 2005-02-17 2006-02-17 Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose DK1848415T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65401205P 2005-02-17 2005-02-17
PCT/US2006/005741 WO2006089164A1 (en) 2005-02-17 2006-02-17 Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1848415T3 true DK1848415T3 (da) 2013-07-08

Family

ID=36916800

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06720863.7T DK1848415T3 (da) 2005-02-17 2006-02-17 Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose

Country Status (12)

Country Link
US (1) US20080261894A1 (da)
EP (1) EP1848415B1 (da)
CA (1) CA2596664A1 (da)
DK (1) DK1848415T3 (da)
ES (1) ES2420404T3 (da)
HR (1) HRP20130622T1 (da)
IL (1) IL184037A0 (da)
PL (1) PL1848415T3 (da)
PT (1) PT1848415E (da)
RS (1) RS52867B (da)
SI (1) SI1848415T1 (da)
WO (1) WO2006089164A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP3199172B1 (en) 2009-08-20 2018-07-11 Yeda Research and Development Co., Ltd. Dosing regimen for multiple sclerosis
EP2298277A1 (en) * 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CA2895359A1 (en) * 2012-12-21 2014-06-26 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US4529811A (en) * 1981-03-02 1985-07-16 G. D. Searle & Co. Process for isolating organic compounds and lithium salt complexes useful in said process
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ATE292619T1 (de) * 1996-12-18 2005-04-15 Teva Pharma Aminoindanderivate
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040013643A1 (en) * 2000-09-19 2004-01-22 Novlmmune S.A. Methods for treatment of multiple sclerosis with statins
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
BR0307975A (pt) * 2002-02-25 2005-01-11 Elan Pharm Inc Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
CA2534711A1 (en) * 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
SI2177528T1 (sl) * 2004-09-09 2012-04-30 Teva Pharma Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
EA016843B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Таннат разагилина
MX2009006251A (es) * 2006-12-14 2009-10-12 Teva Pharma Base de rasagilina solida cristalina.
JP2011504925A (ja) * 2007-11-28 2011-02-17 テバ ファーマシューティカル インダストリーズ リミティド 臨床的に確実な多発性硬化症の発症を遅延させる方法

Also Published As

Publication number Publication date
HRP20130622T1 (en) 2013-08-31
EP1848415A4 (en) 2010-05-26
CA2596664A1 (en) 2006-08-24
EP1848415A1 (en) 2007-10-31
PL1848415T3 (pl) 2013-10-31
PT1848415E (pt) 2013-06-27
ES2420404T3 (es) 2013-08-23
SI1848415T1 (sl) 2013-08-30
EP1848415B1 (en) 2013-04-03
WO2006089164A1 (en) 2006-08-24
IL184037A0 (en) 2008-12-29
US20080261894A1 (en) 2008-10-23
RS52867B (en) 2013-12-31

Similar Documents

Publication Publication Date Title
DK1848415T3 (da) Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1638589T3 (da) Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose
IL180992A0 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
IL186194A0 (en) Markers associated with the therapeutic efficacy of glatiramer acetate
DK1773361T4 (da) Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme
DK1889065T3 (da) Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK2139517T3 (da) Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
PT1998730T (pt) Novo sistema de suporte para o tratamento e prevenção de doenças das veias
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
DK1709082T3 (da) Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
EP1805210A4 (en) NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DK1812797T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af hyperproliferative sygdomme